Background. Risk-adjusted control charts have become popular for monitoring processes that involve the management and treatment of patients in hospitals or other healthcare institutions. However, to date, the effect of estimation error on risk-adjusted control charts has not been studied.
Introduction
Control charts have been used for quality monitoring of industrial processes for many years. At the design stage, typically a stable (in-control) process is sampled over a period of time and the observed data are used to estimate parameters so that the distribution of the stable process can be determined. This stage of the monitoring process is called 'Phase I' data collection [1] . This estimated distribution is used to design a control chart to monitor the process to ensure it remains in control or conversely to provide a timely signal when it goes out of control. An obvious symptom of an out-of-control process is a change in the mean and/or variation. Clearly, the performance of the control chart will be influenced by the precision of the parameter estimates used to design the chart. In this (industrial) context, there have been a number of studies that have assessed the effect of parameter estimation on control chart performance. For a review of these studies, see ref. [2] .
In recent years, control charts have become popular for monitoring processes that involve the management and treatment of patients in hospitals or other healthcare institutions. Unlike most industrial processes where each unit of observation is intended to be the same, patients are heterogeneous and this needs to be considered when designing control charts. This can be achieved by estimating and taking into account individual patient risks in the monitoring process. Control charts that implement this procedure are often referred to as risk-adjusted control charts. Steiner et al. [3] developed a risk-adjusted cumulative sum (CUSUM) control chart appropriate for binary (adverse) events, which are the type of events (along with counts and rates) most commonly encountered in the health context. The risk adjustment is achieved by estimating each patient's risk of an adverse event, e.g. using a logistic regression model and updating the CUSUM chart with a likelihood-based scoring method. These scores are used, in conjunction with actual patient outcomes, to produce weights for inclusion in a CUSUM control chart. As in the industrial context, the performance of risk-adjusted control charts will be influenced by the precision of the estimated parameters used to derive the patient risk scores. Moreover, the added complexity of risk adjustment means that the previous studies of the effect of parameter estimation on control chart performance may not be relevant.
In this healthcare context, estimation error is the error associated with estimating the risk of an adverse event for each patient as well as estimating the proportion of patients in each risk group (the patient mix). In a simplified version of the real example, we use later in this study, there could be three risk groups in a population of around 7000 patients undergoing coronary artery bypass surgery: low, medium and high, with risk of 30-day mortality of 3, 9 and 21%, respectively. In addition, suppose the proportion of patients in each risk group is 62, 25 and 13%, respectively. Estimation error occurs because population parameters are estimated using a sample which is subject to sampling error due to random variation.
In this article, we assess the effect of estimation error on the performance of risk-adjusted CUSUM control charts. In addition, the effect of important variables such as adverse event rate, patient variability and desired average run length for an in-control process (ARL 0 ) on estimation error is investigated. In one scenario, we assume patients having a uniform adverse event risk, i.e. no risk adjustment is required. While Steiner et al. [3] reported on a small simulation study showing the sensitivity of their risk-adjusted CUSUM procedure to the initial estimate of patient mix and regression parameters, to our knowledge this is the first time the effect of estimation error has been systematically studied in the case of a simple binary CUSUM. We assume that the risk-adjustment model is correct, i.e. there is no confounding bias and important explanatory variables are not missing from the model. Assessing the performance of risk-adjusted control charts with modeling error is beyond the scope of this study.
Methods
To set up risk-adjusted control charts, we need estimates of:
(i) the patient mix, i.e. the ( joint) distribution of the covariates and (ii) the risk-adjustment model, e.g. a logistic regression model fit for a binary outcome. We assume a single continuous covariate, e.g. Parsonnet score ( predictive score for acquired adult heart surgery) [4] , denoted by z. The patient mix (distribution of z) is denoted by f(z) and the risk-adjustment model:
The risk-adjusted CUSUM procedure [3] involves sequentially monitoring:
where X 0 ¼0 and W t is the score for the tth patient, which is defined as
where y t is the outcome of interest for patient t, with 1 indicating the outcome occurred and 0 indicating it did not occur; p t is the estimated ( prior) risk of having the outcome for patient t; R 0 is the odds ratio under the null hypothesis (often R 0 ¼1.0) and R A is the odds ratio under the alternative hypothesis of a pre-specified clinically important increase (or decrease) in the outcome of interest. The CUSUM signals when X t !h where h is the pre-specified control limit. For the risk-adjustment model in Equation (1):
We assume that there are a discrete number of possible patient types, e.g. Parsonnet scores are integers, so f(z) gives the multinomial probabilities of the various possible values for z and Y is a discrete outcome like 30-day mortality (yes or no). Let us then assume that the true patient mix and risk adjustment are given. Then, when we plan to implement a control chart we would collect some Phase I data and use these data to estimate both the patient mix (based on the observed distribution of Parsonnet scores) and the risk-adjustment model. We will assume here that there are no errors in the measurement of the covariates and that we use the correct covariates in building the risk-adjustment model.
To determine the effect of estimation error, we repeat the following:
(i) Generate some sample Phase I data (z i ,y i ) where i¼1, 2,. . . ,n, using the (assumed) true patient mix and risk-adjustment model. (ii) Use the data to estimate the patient mix and the parameters of the risk-adjustment model. (iii) Use the estimated patient mix and risk-adjustment model to set up a CUSUM chart (i.e. determine the control limit, h) that will yield some desired value for the in-control ARL 0 . The appropriate control limit can be determined by repeatedly using the Markov chain approximation [5] with different values of the threshold (control limit) until an appropriate threshold is found (see the Appendix for details). (iv) Given the selected threshold and the true patient mix and risk-adjustment model, determine the actual in-control ARL 0 and out-of-control ARL 1 (for a realistic and clinically important increase in the true adverse event rate) that would be obtained. ARL 1 is approximated in the same way as ARL 0 but with the adverse event rate increased by the pre-specified clinically important amount, as defined by an odds ratio. Repeating steps 1 -4 many times gives the distribution for the actual ARL 0 and ARL 1 . The effect of the estimation error will be indicated by the variability of the ARLs. To illustrate, let us consider the simplified example from the introduction with three risk groups of patients in a population of around 7000 patients and further assume that a control limit of 3.0 equates to an ARL 0 of 1000. First, we take a random sample of 1000 patients from the population and fit a logistic model to the sample data. Let's say we observe that 55% of our sample patients are at low risk, 30% at medium risk and 15% at high risk. The logistic model fit to these data suggests low-risk patients having 4% risk of infection, medium-risk patients of 10% and high-risk patients a 25% risk of infection. Based on the sample data, we estimate that a control limit of 3.2 is required for an ARL 0 of 1000. Given this control limit of 3.2, the true ARL 0 is actually 1200 for the population of 7000. Therefore, in this simplified example, we can see that the effect of estimation error has resulted in a control limit that is higher than what is required, an ARL 0 higher than what is assumed, and consequently the ARL 1 will be longer than expected, thus it will take longer to detect a clinically important increase in the 30-day mortality rate than expected.
We used both actual data and simulated data to assess the effect of estimation error. The actual data have been used previously [3] and these are data on a cohort of 6994 patients from the UK who underwent coronary bypass graft surgery (CABG) between 1 January 1992 and 31 December 1998. The adverse event of primary interest was 30-day mortality, which occurred in 6.6% of patients. Previous analysis determined that a strong predictor of 30-day mortality was Parsonnet score, which ranged in this cohort from 0 to 71. The fitted risk-adjustment model logit(y)¼3.6320.074z predicts a 2.5% risk of death at 30 days for patients with Parsonnet¼0 and an 84% risk of death at 30 days for patients with Parsonnet¼71. The area under the receiver operator characteristic curve (AUC) is a commonly reported measure of goodness of fit for a logistic regression model [6] . The AUC for this model is 0.76, indicating typical discrimination between higher and lower risk patients for a predictive model in the medical literature. For the purposes of this study, we assume that the patient mix of the 6994 patients and the logistic model that describes the relationship between Parsonnet score and 30-day mortality are correct and not subject to error. Based on this cohort, a control limit¼2.71 equates to ARL 0 1000 patients and an ARL 1 110 patients assuming a doubling of the odds of 30-day mortality. In this example, we have assumed that a doubling of the odds of mortality is a clinically meaningful increase; however, we could have assumed a 50% increase of the odds or a tripling of the odds. The magnitude of the pre-specified increase will impact the control chart performance such that the performance is optimal at a true increase that is the same as the pre-specified increase and larger increases will be detected in a more timely fashion than smaller increases.
To determine the effect of estimation error on the variability of ARL, we randomly selected samples with replacement from the 6994 patients in the cohort. The samples were of sizes 760, 1520, 2280, 3040 and 3800 patients resulting in expected number of deaths equal to 50, 100, 150, 200 and 250, respectively (assuming 6.6% mortality). In total, 1000 samples of each sample size were taken. The procedure given above (steps 1-4) was used with specified ARL 0 1000 patients. In addition, the variance of the 'true' in-control run length and the 'true' ARL 1 based on a doubling of the odds of 30-day mortality were calculated. This procedure was repeated for ARL 0 500 and 1500 using a sample size of 1520 patients to investigate the effect of the specified ARL 0 on estimation error.
In additional analyses, we varied the adverse event rate and the variation in patient mix to determine how these important variables affect estimation error. To investigate the effect of the adverse event rate, we modified the logistic model by changing the size of the intercept term to manipulate the average adverse event rate to 3.5% and also to 12.2%. The model equations specified were logit (y)¼4.3620.074z and logit (y)¼2.8820.074z, respectively. The variability of the patient mix in the CABG cohort was large (i.e. risks of adverse events in individuals ranged from very small to very large) and hence we lowered variation by restricting sampling to the lower end of the actual Parsonnet distribution (i.e. patients with Parsonnet scores of 20). This could occur in practice, for example, if only low-risk patients were accepted for the procedure. The model equation for this scenario was logit(y)¼4.0220.114z. For these additional analyses, we bootstrap [7] sampled the Parsonnet scores from the actual CABG cohort and used the modified logistic model to derive patient mortality risks. We then used these estimated risks to generate a random Bernoulli outcome (adverse event¼yes or no) with P (adverse event)¼ risk probability using the RAND ('Bernoulli', risk) function in SAS. In the case where we restricted sampling to patients with Parsonnet scores of 20 we assumed that the restricted data set was the true patient mix and the fitted logistic model was the correct risk-adjustment model. In a final scenario, we assumed completely homogeneous patients where the adverse event risk was the same for each patient. The model equation in this case was logit (y)¼2.65 giving a uniform risk of 6.6% for each patient.
As recommended by Burton et al. [8] , we wrote a protocol prior to conducting the simulation procedure described above. SAS, version 9.2 for Windows (SAS Institute, Cary, NC) was used for the analysis. PROC SURVEYSELECT was used to select the samples with the starting seeds generated using the system clock. All the estimates obtained from the samples (including control limits and ARLs) are stored in Microsoft Office Excel version 97-2003 worksheets. We chose 1000 samples for each scenario so that we could estimate the variance of the ARL with standard deviation (SD) of ,5% of the variance. Each simulation took between 5 and 10 min and hence time was also a factor in deciding how many simulations to run. Table 1 shows the results of the 1000 samples taken for each of 5 sample sizes. The first row of data is for a sample size of 760 patients and specified ARL 0 1000. Although a control limit of 2.71 is required for ARL 0 1000, due to sampling error the actual threshold values for the 1000 samples ranged between 2.25 and 3.01 (with mean of 2.71 and SD of 0.11). This variation in control limit was sufficient to vary the true ARL 0 from 564 to 1420 (with mean of 1008 and SD of 131.5). The variability in the true ARLs and SD of the true in-control run length (SDRL 0 ) unsurprisingly decrease as the sample size increases. However, on closer inspection, it can be seen that as sample size doubles, the variation halves and hence the SD decreases by a factor of p 2. If sampling variation is taken into consideration (Table 2) , then the observed data are consistent with an exact reciprocal relationship between sample size and variability.
Results
The effect of specifying a different ARL 0 on the estimation error is shown in Table 3 (and Table 2 ). The data show a relationship between specified ARL 0 and SD of the true ARL 0 where SD doubles as specified ARL 0 doubles. This relationship is also apparent for SDRL 0 but not for ARL 1 , where the SD of true ARL 1 is only moderately increased for specified ARL 0 ¼1000 compared with specified ARL 0 ¼500 but virtually unchanged for specified ARL 0 ¼1500 compared with specified ARL 0 ¼1000. Table 4 (and Table 2 ) show a relationship between adverse event rate and estimation error similar to that observed for sample size. As the event rate (approximately) doubles, the variation in the true ARL and the true SD of run length (approximately) halves. Hence, the SD decreases by a factor of p 2. However, this relationship does not hold for ARL 1 where there is a reciprocal association between event rate and SD of the true ARL 1 . In other words, the effect of event rate on the estimation error effect is more pronounced for ARL 1 compared with ARL 0 .
In another analysis, the effect of lower variation in patient mix was investigated. A Parsonnet score of 20 is associated with a 30-day mortality risk of 10% and hence by restricting procedures to patients with Parsonnet scores 20 we are in effect restricting CABG procedures to patients with a 30-day mortality risk of no .10%. This restriction resulted in removing 11% of the total cohort leaving 6211 patients for the analysis with 4.6% of patients dying within 30 days. The results are similar to what would have been expected using all 6994 patients and 69 expected deaths and hence it appears, in this case, a more homogeneous group of patients has had little effect on the effects of estimation error (Table 5) . If completely homogeneous patients are assumed, where no risk adjustment is necessary, estimation error is reduced but remains high (Table 5 ).
Discussion
In this study, we have shown that estimation error can have a substantial effect on risk-adjusted CUSUM chart performance. If we assume that Phase I data include 50 adverse events, a specified ARL 0 of 1000 and a typical risk-adjustment model then the true ARL 0 could be as low as 564 or as high as 1420 based on our 1000 simulations. Therefore, although one false alarm is assumed for every 1000 patients, in fact it could be as high as one in every 564 patients or as low as one in every 1420 patients. In terms of ARL 1 , the assumed value is 110 but in fact the true value could be as low as 86 or as high as 125. This difference in ARL 1 between these two extreme scenarios is equivalent to a difference of three additional adverse events, assuming an in-control adverse event rate of 6.6% and a doubling of the odds of adverse event under the alternative hypothesis.
When considering whether to delay Phase II monitoring until a substantial number of events have been included in Phase I data collection (to minimize potential estimation error), it might be better to avoid delay and move to an initial Phase II stage where model parameters continue to be updated but patient monitoring is also implemented prospectively. However, care is needed to ensure that model parameters are updated using only in-control observations and avoiding observations from periods where the system is out of control. In addition, the effect of estimation error when designing a control chart could be taken into account. This could be done by generating a number of bootstrap samples of the available phase I data and then, for each sample, determining the control limit needed to obtain an ARL0 of a pre-specified level. To determine the ultimate control limit to implement, a value that maintains an ARL 0 of at least the pre-specified level in (say) 95% of the samples could be chosen. For example, in our scenario of 100 adverse events and a specified ARL 0 of 1000, a control limit of 2.84 maintains an ARL 0 of at least 1000 in 95% of the samples. This contrasts with an average control limit of 2.71 if we simply aim for an ARL 0 of 1000. However, this is a conservative strategy with the trade-off that the control chart will be slower to detect a clinically important deterioration in the adverse event rate. Variables thought to potentially influence estimation error considered in this research included Phase I sample size, number of adverse events, specified ARL 0 and patient variability. The two most important variables were unsurprisingly the number of events and the specified ARL 0 . In terms of the number of adverse events, as the number of events doubles, the variance of the true ARL 0 halves. However, interestingly the effect on true ARL 1 is even more pronounced where it is the SD that halves. In the case of specified ARL 0 , the effect of estimation error decreases as the specified ARL 0 decreases. This relationship was strong for true ARL 0 where the SD halved when the specified ARL 0 was halved; however, the relationship was weak for true ARL 1 where the SD only decreased slightly when the specified ARL 0 was reduced by a factor of 3. A third variable, patient risk variability, appeared to have little effect on the estimation error. In the case of homogeneous patients where adverse event risk was assumed to be constant at 6.6%, the estimated level of estimation error: SD (ARL 0 )¼79.7 was less than the equivalent risk-adjusted scenario where SD (ARL 0 )¼89.2 but only by around 10%. This result suggests that it is the uncertainty in the overall adverse event rate that is the main component of estimation error. The uncertainties of the patient mix and risk-adjustment model, whilst not ignorable, only appear to account for a modest proportion of the total estimation error.
There are a number of important limitations of this study. First of all, we only used one example data set; therefore, our results may not generalize to all relevant situations where risk-adjusted control charts are implemented. In addition, we only considered risk-adjusted CUSUM charts where risk adjustment was done by the method of Steiner et al. [3] . However, we did use a more general set of simulated patients in the analyses that investigated the effects of event rate and patient variability on estimation error. We also varied a number of important variables such as sample size and specified ARL 0 to make our results more generalizable. Another limitation is that we used an approximate method for determining the ARLs. The Markov chain method is associated with some error due to the state space being divided into a discrete number of states. However, we minimized this error by including a large number of states in the transition matrices: between 1000 and 1500 in most cases. With these large matrices, each simulation took around 5-10 min to run. A further limitation was our use of simulations to investigate the relationship between estimation error and control chart performance. Therefore, our results are not exact; however, we included 1000 simulations for each scenario investigated and, therefore, the 95% confidence intervals for estimated SDs of the true ARLs were relatively narrow. These confidence intervals were sufficiently tight to allow us to determine the exact relationships between important variables such as number of events and the magnitude of estimation error. A final limitation is that we have assumed that the risk-adjustment model is correct and not subject to confounding bias. If a risk-adjustment model is not correct, then the results of this study would not be applicable.
